$LFST Balance Sheet | Understand Stock

$LFST

$13.12 +$0.06 (0.46%) Live

$LFST Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
CURRENT ASSETS
Cash and cash equivalents
Patient accounts receivable, net
Prepaid expenses and other current assets
Total current assets
NONCURRENT ASSETS
Property and equipment, net
Right-of-use assets
Intangible assets, net
Goodwill
Deposits
Other noncurrent assets
Total noncurrent assets

Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable
Accrued payroll expenses
Other accrued expenses
Contingent consideration
Operating lease liabilities, current
Other current liabilities
Total current liabilities
NONCURRENT LIABILITIES
Long-term debt, net
Operating lease liabilities, noncurrent
Contingent consideration, net of current portion
Deferred tax liability, net
Other noncurrent liabilities
Total noncurrent liabilities

Total liabilities
Redeemable Class A units – 0 and 35,000 units authorized, issued and outstanding as of December 31, 2021 and December 31, 2020, respectively
STOCKHOLDERS' EQUITY
Common Unit, Issuance Value
Preferred stock - par value $0.01 per share; 25,000 shares authorized as of June 30,2026 and December 31, 2025; 0 shares issued and outstanding as of june 30,2026 and December 31,2025, respectively
Common stock - par value $0.01 per share; 800,000 shares authorized as of June 30, 2026 and December 31, 2025; 382,022 and 388,318 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Total stockholders' equity

Total liabilities and stockholders' equity

Comments